95933-74-7 Usage
Description
TRIMIDOX, also known as Trimidox, is a specific ribonucleotide reductase inhibitor that targets the rate-limiting enzyme for de novo DNA synthesis. It is effective in reducing the levels of dGTP and dCTP in HL-60 cells, which leads to the induction of apoptosis via the activation of caspases without affecting the cell cycle distribution. TRIMIDOX demonstrates its inhibitory effect on the growth of human promyelocytic leukemia HL-60 cells with an IC50 value of 35 μM.
Uses
Used in Cancer Treatment:
TRIMIDOX is used as a chemotherapy agent for targeting ribonucleotide reductase, an enzyme with increased activity in cancer cells. This inhibition helps in controlling malignant transformation and proliferation, making it a potential candidate for cancer treatment.
references
[1] szekeres t, fritzer m, strobl h, et al. synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia hl-60 cells[j]. blood, 1994, 84(12): 4316-4321.[2] elledge s j, zhou z, allen j b. ribonucleotide reductase: regulation, regulation, regulation[j]. trends in biochemical sciences, 1992, 17(3): 119-123.
Check Digit Verification of cas no
The CAS Registry Mumber 95933-74-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,5,9,3 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 95933-74:
(7*9)+(6*5)+(5*9)+(4*3)+(3*3)+(2*7)+(1*4)=177
177 % 10 = 7
So 95933-74-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H8N2O4/c8-7(9-13)3-1-4(10)6(12)5(11)2-3/h1-2,9-11,13H,8H2
95933-74-7Relevant articles and documents
Methods for treating or preventing neuroinflammation or autoimmune diseases
-
Page/Page column 22, (2017/01/19)
Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.